Literature DB >> 3582175

Pentobarbital pharmacokinetics in patients with severe head injury.

D P Wermeling, R A Blouin, W H Porter, R P Rapp, P A Tibbs.   

Abstract

Intravenous administration of high-dose pentobarbital has been proposed as a treatment for elevated intracranial pressure refractory to other measures in brain-injured patients. The purpose of this clinical study was to examine the pharmacokinetics of high-dose continuous intravenous infusion of pentobarbital in this critical care setting. Six patients received a 25-34 mg/kg intravenous loading dose followed by a 1-3 mg/kg/h continuous infusion for 61-190 hours. Dosing rates were adjusted based on the patient's clinical status. The mean clearance was 0.72 ml/min/kg, with a volume of distribution (Vd) of 1.03 L/kg and a terminal half-life of 19.1 h. Considerable variation in individual patient parameters was observed. In addition, a change in clearance was suggested in patients requiring a longer infusion duration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3582175     DOI: 10.1177/106002808702100517

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  6 in total

1.  Population pharmacokinetics of pentobarbital in neonates, infants, and children after open heart surgery.

Authors:  Athena F Zuppa; Susan C Nicolson; Jeffrey S Barrett; Marc R Gastonguay
Journal:  J Pediatr       Date:  2011-06-12       Impact factor: 4.406

Review 2.  Pharmacodynamics and pharmacokinetics of thiopental.

Authors:  H Russo; F Bressolle
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

Review 3.  Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients.

Authors:  B K Wagner; D A O'Hara
Journal:  Clin Pharmacokinet       Date:  1997-12       Impact factor: 6.447

Review 4.  Pharmacokinetic alterations after severe head injury. Clinical relevance.

Authors:  B A Boucher; S D Hanes
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 6.447

Review 5.  Antiepileptic drugs in critically ill patients.

Authors:  Salia Farrokh; Pouya Tahsili-Fahadan; Eva K Ritzl; John J Lewin; Marek A Mirski
Journal:  Crit Care       Date:  2018-06-07       Impact factor: 9.097

Review 6.  Super-Refractory Status Epilepticus: Prognosis and Recent Advances in Management.

Authors:  Batool F Kirmani; Katherine Au; Lena Ayari; Marita John; Padmashri Shetty; Robert J Delorenzo
Journal:  Aging Dis       Date:  2021-07-01       Impact factor: 6.745

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.